Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Renal Denervation in ADPKD- RDN-ADPKD Study

NCT: NCT05460169 · ACTIVE_NOT_RECRUITING

NCT IDNCT05460169
StatusACTIVE_NOT_RECRUITING
Start Date2022-06-14
Completion2028-03

Brief Summary

RDN-ADPKD is a prospective, randomized (1:1, central randomization), single-center, hypothesis-generating, feasibility study. The purpose of the RDN-ADPKD study is to demonstrate efficacy and document safety of renal denervation (RDN) with the Paradise System in hypertensive patients with ADPKD.

Frequently Asked Questions

What is Renal Denervation in ADPKD- RDN-ADPKD Study?

Renal Denervation in ADPKD- RDN-ADPKD Study is a clinical trial registered under NCT05460169. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05460169?

The current status of NCT05460169 (Renal Denervation in ADPKD- RDN-ADPKD Study) is: ACTIVE_NOT_RECRUITING.

When did Renal Denervation in ADPKD- RDN-ADPKD Study start?

Renal Denervation in ADPKD- RDN-ADPKD Study started on 2022-06-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑